Amphastar Pharmaceuticals Inc. (AMPH)
Amphastar Pharmaceuticals (AMPH) Q4 Earnings and Revenues Lag Estimates
Amphastar Pharmaceuticals (AMPH) came out with quarterly earnings of $0.73 per share, missing the Zacks Consensus Estimate of $0.97 per share. This compares to earnings of $0.92 per share a year ago.
Amphastar Pharmaceuticals, Inc. (AMPH) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Amphastar Pharmaceuticals, Inc. (AMPH) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Amphastar Pharmaceuticals, Inc. (AMPH) Q3 2025 Earnings Call Transcript
Amphastar Pharmaceuticals, Inc. ( AMPH ) Q3 2025 Earnings Call November 6, 2025 5:00 PM EST Company Participants Dan Dischner - Senior Vice President of Human Resources & Corporate Communication William Peters - CFO, Executive VP of Finance, Treasurer & Director Tony Marrs - Executive VP of Regulatory Affairs & Clinical Operations Conference Call Participants Serge Belanger - Needham & Company, LLC, Research Division Pavan Patel - BofA Securities, Research Division Ekaterina Knyazkova - JPMorgan Chase & Co, Research Division David Amsellem - Piper Sandler & Co., Research Division Benjamin Burnett - Wells Fargo Securities, LLC, Research Division Presentation Operator Greetings, and welcome to the Amphastar Pharmaceuticals, Inc. Third Quarter Earnings Call. [Operator Instructions] Please note that certain statements made during this call regarding matters that are not historical facts, including, but not limited to, management's outlook or predictions for the future periods are forward-looking statements.
Analysts Estimate Amphastar Pharmaceuticals (AMPH) to Report a Decline in Earnings: What to Look Out for
Amphastar (AMPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Are Investors Undervaluing Amphastar Pharmaceuticals (AMPH) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Amphastar Pharmaceuticals, Inc. (AMPH) Q2 2025 Earnings Call Transcript
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH ) Q2 2025 Earnings Conference Call August 7, 2025 5:00 PM ET Company Participants Dan Dischner - Senior Vice President of Human Resources & Corporate Communication Tony Marrs - Executive VP of Regulatory Affairs & Clinical Operations William J. Peters - CFO, Executive VP of Finance, Treasurer & Director Conference Call Participants David A.
Amphastar (AMPH) Reports Q2 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Amphastar (AMPH) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Amphastar Pharmaceuticals (AMPH) Q2 Earnings and Revenues Beat Estimates
Amphastar Pharmaceuticals (AMPH) came out with quarterly earnings of $0.85 per share, beating the Zacks Consensus Estimate of $0.71 per share. This compares to earnings of $0.94 per share a year ago.
Analysts Estimate Amphastar Pharmaceuticals (AMPH) to Report a Decline in Earnings: What to Look Out for
Amphastar (AMPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amphastar Pharmaceuticals: Shares Are Interesting, And Options Even More
Amphastar is undervalued (~71% upside), but lacks an economic moat and faces modest growth, so I favor a cautious gradual strategy. The business is defensive, with a diversified product mix and pipeline, but faces headwinds from competition, tariffs, and patent expirations. My base-case DCF-based fair value is $38.23; even in a pessimistic scenario, the stock seems at least fairly valued, limiting downside risk.
What Makes Amphastar (AMPH) a New Buy Stock
Amphastar (AMPH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Should Value Investors Buy Amphastar Pharmaceuticals (AMPH) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
